ETHIC trial: Early LMWH in symptomatic COVID-19 positive patients

Phase 3

• Conditions: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

• Registration Number: CTRI/2021/01/030373
• Lead Sponsor: Thrombosis Research Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Male or female, age equal or greater than 55 years but no upper age limit

At least two of the following additional risk factors:

Age equal or greater than 70 years

Body mass index > 25 kg/m2

Chronic obstructive pulmonary disease (COPD)

Diabetes

Cardiovascular disease

Corticosteroid use

Exclusion Criteria

�Contraindications to unfractionated heparin or LMWH

�Recent ( <48 hours) or planned spinal or epidural anesthesia or puncture, PCI or thrombolytic therapy within the preceding 24 hours

�Increased risk for bleeding complications (liver disease, recent haemorrhagic stroke, prior major bleeding or predisposition to bleeding, alcohol use)

�Pregnant women

�Severe renal impairment (GFR < 30 mL/min)

�Receiving any antiplatelet therapy (with the exception of low dose (�100mg) aspirin) or anticoagulant therapy (e.g. VKA, DOAC)

�Patients participating in an interventional study that is outside the purview of TRI sponsored studies.

Study & Design

• Study Type: Interventional
• Study Design: Not specified